Novii+ wireless maternal and fetal monitoring solution cleared by the fda for monitoring approximately 95% of all eligible births in the united states1

Chicago--(business wire)--ge healthcare (nasdaq: gehc) today announced it has received 510(k) clearance from the united states food and drug administration (fda) for novii™+ wireless patch solution. the antepartum and intrapartum maternal and fetal monitor noninvasively measures and displays fetal heart rate, maternal heart rate and uterine activity, so care teams can have a real-time view of patient data. through its belt-free and wireless design, novii+ enables mobility and freedom for mother.
GEHC Ratings Summary
GEHC Quant Ranking